Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDAP NASDAQ:OBIO NASDAQ:RCEL NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDAPEDAP TMS$2.45-6.1%$1.69$1.21▼$3.29$97.59M-0.21175,244 shs52,447 shsOBIOOrchestra BioMed$2.57-1.9%$2.82$2.37▼$6.50$101.25M0.61257,508 shs119,272 shsRCELAvita Medical$4.56+4.1%$5.10$3.60▼$14.16$116.59M1.58272,155 shs293,334 shsVVOSVivos Therapeutics$3.47-4.7%$4.84$1.98▼$7.95$27.32M7.02135,738 shs98,859 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDAPEDAP TMS-1.88%+3.57%+91.91%+52.63%-19.20%OBIOOrchestra BioMed+0.38%-4.38%-3.68%-15.21%-53.95%RCELAvita Medical+5.04%+2.10%-20.65%-20.94%-54.23%VVOSVivos Therapeutics-4.46%-17.27%-23.37%+70.09%+19.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDAPEDAP TMS$2.45-6.1%$1.69$1.21▼$3.29$97.59M-0.21175,244 shs52,447 shsOBIOOrchestra BioMed$2.57-1.9%$2.82$2.37▼$6.50$101.25M0.61257,508 shs119,272 shsRCELAvita Medical$4.56+4.1%$5.10$3.60▼$14.16$116.59M1.58272,155 shs293,334 shsVVOSVivos Therapeutics$3.47-4.7%$4.84$1.98▼$7.95$27.32M7.02135,738 shs98,859 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDAPEDAP TMS-1.88%+3.57%+91.91%+52.63%-19.20%OBIOOrchestra BioMed+0.38%-4.38%-3.68%-15.21%-53.95%RCELAvita Medical+5.04%+2.10%-20.65%-20.94%-54.23%VVOSVivos Therapeutics-4.46%-17.27%-23.37%+70.09%+19.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDAPEDAP TMS 2.33Hold$8.50246.94% UpsideOBIOOrchestra BioMed 3.00Buy$13.50425.29% UpsideRCELAvita Medical 2.40Hold$11.60154.39% UpsideVVOSVivos Therapeutics 2.50Moderate Buy$4.9241.69% UpsideCurrent Analyst Ratings BreakdownLatest VVOS, RCEL, OBIO, and EDAP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.20 ➝ $6.509/5/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $14.009/4/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.008/20/2025OBIOOrchestra BioMedBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/11/2025RCELAvita MedicalLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $8.008/8/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $18.008/8/2025RCELAvita MedicalBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$3.008/7/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDAPEDAP TMS$69.18M1.32N/AN/A$1.18 per share2.08OBIOOrchestra BioMed$2.64M37.62N/AN/A$0.87 per share2.95RCELAvita Medical$64.25M1.89N/AN/A$0.17 per share26.82VVOSVivos Therapeutics$15.03M1.73N/AN/A$1.35 per share2.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDAPEDAP TMS-$20.58M-$0.61N/AN/AN/A-33.49%-56.85%-26.83%11/6/2025 (Estimated)OBIOOrchestra BioMed-$61.02M-$1.83N/AN/AN/A-2,367.49%-289.42%-110.04%11/11/2025 (Estimated)RCELAvita Medical-$61.85M-$1.97N/AN/AN/A-68.87%-632.62%-71.52%11/6/2025 (Estimated)VVOSVivos Therapeutics-$11.14M-$1.68N/AN/AN/A-99.49%-232.76%-84.30%11/13/2025 (Estimated)Latest VVOS, RCEL, OBIO, and EDAP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025VVOSVivos Therapeutics-$0.39-$0.55-$0.16-$0.55$3.37 million$3.82 million8/12/2025Q2 2025OBIOOrchestra BioMed-$0.51-$0.50+$0.01-$0.50$0.78 million$0.84 million8/7/2025Q2 2025RCELAvita Medical-$0.26-$0.38-$0.12-$0.38$34.27 million$18.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDAPEDAP TMSN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDAPEDAP TMS0.041.511.05OBIOOrchestra BioMed48.762.102.09RCELAvita Medical9.390.580.46VVOSVivos Therapeutics1.691.051.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDAPEDAP TMS62.74%OBIOOrchestra BioMed53.20%RCELAvita Medical27.66%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipEDAPEDAP TMS0.23%OBIOOrchestra BioMed8.10%RCELAvita Medical2.80%VVOSVivos Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDAPEDAP TMS23037.39 million37.31 millionOptionableOBIOOrchestra BioMed438.64 million35.51 millionNot OptionableRCELAvita Medical13026.62 million25.87 millionOptionableVVOSVivos Therapeutics1607.50 million7.28 millionOptionableVVOS, RCEL, OBIO, and EDAP HeadlinesRecent News About These CompaniesAscendiant Capital Markets Issues Positive Forecast for Vivos Therapeutics (NASDAQ:VVOS) Stock PriceSeptember 11 at 2:04 AM | americanbankingnews.comVivos Therapeutics’ Earnings Call: Strategic Transition and GrowthAugust 31, 2025 | tipranks.comVivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call TranscriptAugust 22, 2025 | seekingalpha.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2025 Earnings Call TranscriptAugust 21, 2025 | msn.comVivos Reports 7% Sales DropAugust 21, 2025 | aol.comAVivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateAugust 20, 2025 | finanznachrichten.deVivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateAugust 19, 2025 | globenewswire.comVivos Therapeutics, Inc. Announces Upcoming Release of Second Quarter 2025 Financial Results and Conference CallAugust 19, 2025 | quiverquant.comQVivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference CallAugust 19, 2025 | globenewswire.comVivos Therapeutics Delays Q2 2025 10-Q FilingAugust 14, 2025 | msn.comVivos Therapeutics Adds to Management Team to Support Expansion and GrowthJuly 30, 2025 | finance.yahoo.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance - MorningstarJuly 2, 2025 | morningstar.comMVivos Therapeutics Inc. (VVOS) Stock Price Today - WSJJuly 2, 2025 | wsj.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral ApplianceJuly 1, 2025 | taiwannews.com.twTVivos Therapeutics stock soars after Medicare approves VidaSleep oral applianceJuly 1, 2025 | in.investing.comVivos Therapeutics Shares Skyrocket After Medicare Greenlights VidaSleep Oral DeviceJuly 1, 2025 | msn.comVivos Therapeutics Secures CMS Approval for VidaSleep™ Oral Appliance, Expanding Access to Sleep Apnea TreatmentJuly 1, 2025 | quiverquant.comQNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | finance.yahoo.comNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | globenewswire.comVivos Therapeutics, Inc: Vivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVVOS, RCEL, OBIO, and EDAP Company DescriptionsEDAP TMS NASDAQ:EDAP$2.45 -0.16 (-6.13%) Closing price 04:00 PM EasternExtended Trading$2.45 0.00 (0.00%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.Orchestra BioMed NASDAQ:OBIO$2.57 -0.05 (-1.91%) Closing price 04:00 PM EasternExtended Trading$2.58 +0.01 (+0.19%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Avita Medical NASDAQ:RCEL$4.56 +0.18 (+4.11%) Closing price 04:00 PM EasternExtended Trading$4.55 -0.01 (-0.22%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.Vivos Therapeutics NASDAQ:VVOS$3.47 -0.17 (-4.67%) Closing price 04:00 PM EasternExtended Trading$3.52 +0.05 (+1.41%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
